Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
54.41
-2.93 (-5.12%)
Delayed Quote
Updated: 2:01 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
37
38
Next >
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
↗
March 12, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new
Via
Benzinga
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
↗
March 11, 2024
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.
Via
Talk Markets
The Top 3 Biotech Stocks to Buy in March 2024
↗
March 06, 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.
Via
InvestorPlace
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
↗
February 23, 2024
Via
Benzinga
Smart Money Is Betting Big In CRSP Options
↗
February 22, 2024
Via
Benzinga
Check Out What Whales Are Doing With CRSP
↗
February 14, 2024
Via
Benzinga
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
↗
March 05, 2024
The biotech company keeps moving closer to bringing its promising first gene therapy to market.
Via
The Motley Fool
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
↗
March 04, 2024
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.
Via
InvestorPlace
Topics
Artificial Intelligence
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
↗
February 29, 2024
This company's fortunes are likely to improve, and soon.
Via
The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
↗
February 29, 2024
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Via
The Motley Fool
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
↗
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
3 Biotech Stocks Bound to Blast Off By 2029
↗
February 27, 2024
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.
Via
InvestorPlace
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
↗
February 27, 2024
Vertex shares have climbed almost 50% over the past year.
Via
The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
↗
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
3 Biotech Stocks to Buy and Hold for the Next 10 Years
↗
February 26, 2024
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Via
The Motley Fool
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
↗
February 26, 2024
Buy this stock if you're daring, but avoid it for now if you aren't.
Via
The Motley Fool
Three S&P 500 Giants Lead This List Of Stocks Near Buy Points
↗
February 24, 2024
Watch these five stocks, but the market is slightly extended.
Via
Investor's Business Daily
Topics
Stocks
Stock Market Rallies To Record High On Nvidia: Weekly Review
↗
February 23, 2024
The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More
Via
Investor's Business Daily
Topics
Stocks
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
↗
February 22, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone
↗
February 21, 2024
The company recently gained approval in the U.S. and abroad for its first gene-editing drug.
Via
Investor's Business Daily
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
↗
February 20, 2024
These exciting players could deliver explosive growth over time.
Via
The Motley Fool
If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today
↗
February 19, 2024
It would have been a great move.
Via
The Motley Fool
3 Stocks That Cathie Wood Is Loving Now: February 2024
↗
February 16, 2024
Looking for high-growth opportunities? Here are three Cathie Wood stocks for long-term investors to consider now.
Via
InvestorPlace
What's Going On With Crispr Therapeutics Stock?
↗
February 15, 2024
Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have...
Via
Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
↗
February 15, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Via
Benzinga
Topics
Stocks
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
37
38
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
